Evangelia Sereti, MSc, PhD, a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre, discusses the unmet need addressed with the addition of NOV202 to olaparib (Lynparza) in 

Preclinical findings, which were presented during the 2021 EAU Congress, aimed to evaluate whether NOV202, a vascular-disrupting agent, could increase the anticancer efficacy of the PARP inhibitor olaparib in prostate cancer–based xerograph mouse models with 

This research addresses an urgent clinical need, which is to develop novel, combinational therapeutic strategies that can improve the efficacy observed with single-agent PARP inhibitors, prevent or overcome resistance to PARP inhibitors, and expand the population that may benefit from treatment with PARP inhibitors, Sereti concludes.

Videos

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

Evangelia Sereti, MSc, PhD, a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre, discusses the next steps with the combination of NOV202 and olaparib (Lynparza) in 

Preclinical findings, which were presented during the 2021 EAU Congress, demonstrated promising anticancer effects with NOV202 in 

-mutated prostate cancer xenografts. The agent also demonstrated synergistic effects when combined with the PARP inhibitor olaparib.

Building on these results, another study will evaluate the underlying mechanism of action of NOV202 plus olaparib by immunohistochemistry analysis of collected tissue specimens, says Sereti. Expression of biomarkers, such as DNA repair, DNA damage, hypoxia, and stem cell markers, will be evaluated as part of the study, adds Sereti. 

An additional study using a 50-gene mutational screening panel is ongoing to determine whether mutational status and PARP inhibitor sensitivity is correlated, concludes Sereti. 

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.  



Dr. Sereti on the Next Steps for NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer 

Evangelia Sereti, MSc, PhD, a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre, discusses the preclinical efficacy of NOV202 plus olaparib (Lynparza) in 

NOV202 is an investigational microtubule-targeting and vascular disrupting agent that demonstrated anticancer activity and tumor growth suppression of certain cancers, such as pancreatic and ovarian cancers, in preclinical research. Olaparib is a PARP inhibitor that was FDA approved to treat men with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

During the 2021 EAU Congress, findings from a preclinical study evaluating the 

 anticancer efficacy of NOV202 alone and in combination with olaparib in mouse models harboring 

-mutated prostate cancer cells were presented. The results demonstrated that NOV202 alone induced significant anticancer effects in 

-mutated prostate cancer xenografts. Additionally, NOV202 plus olaparib elicited significant synergistic effects in these xenografts. Notably, the synergistic effects observed after 3 weeks of treatment were maintained after 2 weeks of no treatment. 

As such, NOV202 plus olaparib offers a promising new drug combination for patients with 

-mutated advanced prostate cancer, says Sereti. Additional studies are needed to determine the mechanism of action of the synergistic activity observed preclinically, concludes Sereti.

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells. 

Evangelia Sereti, MSc, PhD

Articles

Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

Dr. Sereti on the Next Steps for NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer